Iwano Masataka, Sadahiro Kohei, Maruo Takuya, Kawarai Shinpei, Kayanuma Hideki, Orito Kensuke
Veterinary Teaching Hospital, Azabu University, 1-17-71 Fuchinobe, Chuo, Sagamihara, Kanagawa 252-5201, Japan.
Laboratory of Veterinary Physiology II, School of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo, Sagamihara, Kanagawa 252-5201, Japan.
J Vet Med Sci. 2021 May 9;83(5):775-779. doi: 10.1292/jvms.20-0653. Epub 2021 Mar 15.
Carboplatin is used to treat certain cancers in dogs and cats and is routinely administered via intravenous drip (IVD). Subcutaneous (SC) administration has also been described. However, the toxicity, serum concentrations, and area under blood concentration-time curves (AUCs) of SC carboplatin are unknown. This study aimed to compare serum carboplatin concentrations in dogs after SC and IVD and to monitor any adverse events. In this crossover study, five dogs received SC or IV carboplatin (300 mg/m). After a minimum of 3 weeks, each dog received the other treatment. No gross skin toxicity or abnormal clinical signs were observed in any of the dogs. Blood test abnormalities were detected in most dogs. Decreased neutrophil and platelet counts, and increased C-reactive protein (CRP) levels were found. There was no significant difference in the neutropenia, thrombocytopenia, and CRP scores between the groups. Systemic toxicities of SC carboplatin were comparable to those of IVD carboplatin. The time to maximum carboplatin concentration after SC was longer than that after IVD (P<0.001). SC carboplatin remained in the serum longer than IVD carboplatin (P=0.008). The AUC of SC was less than that of IVD (P=0.002). The AUC and time taken to reach the maximum concentration of SC carboplatin were lower than those of IVD carboplatin. This study suggests that SC carboplatin may be an efficacious option for the treatment of tumors in dogs, particularly where IVD administration is challenging.
卡铂用于治疗犬猫的某些癌症，通常通过静脉滴注（IVD）给药。也有皮下（SC）给药的描述。然而，皮下注射卡铂的毒性、血清浓度和血药浓度-时间曲线下面积（AUC）尚不清楚。本研究旨在比较犬皮下注射和静脉滴注卡铂后的血清卡铂浓度，并监测任何不良事件。在这项交叉研究中，五只犬接受了皮下或静脉注射卡铂（300mg/m）。至少3周后，每只犬接受另一种治疗。所有犬均未观察到明显的皮肤毒性或异常临床体征。大多数犬检测到血液检查异常。发现中性粒细胞和血小板计数减少，C反应蛋白（CRP）水平升高。两组之间的中性粒细胞减少、血小板减少和CRP评分无显著差异。皮下注射卡铂的全身毒性与静脉滴注卡铂相当。皮下注射后达到卡铂最大浓度的时间比静脉滴注后更长（P<0.001）。皮下注射卡铂在血清中的停留时间比静脉滴注卡铂更长（P=0.008）。皮下注射的AUC小于静脉滴注（P=0.002）。皮下注射卡铂的AUC和达到最大浓度所需的时间低于静脉滴注卡铂。本研究表明，皮下注射卡铂可能是治疗犬肿瘤的一种有效选择，特别是在静脉滴注给药具有挑战性的情况下。
